UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF
SECURITIES
Pursuant to Section 12(b) or (g) of
the Securities Exchange Act of 1934
MEDIFAST, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-31573 |
13-3714405 |
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS. Employer Identification No.) |
3600 Crondall Lane
Owings Mills, Maryland |
21117
|
(Address of Principal Executive Offices) |
(Zip Code) |
(410) 581-8042
Registrant’s telephone number,
including area code
Not Applicable
(Former name or former address if changed
since last report.)
If this form relates to the
registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), please check the following box: x
If this form relates to the registration of a class of securities pursuant
to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following
box: ¨
Securities Act registration statement file
number to which this form relates: Not Applicable.
Securities to be registered pursuant
to Section 12(b) of the Act:
Title of Each Class to
be so Registered
|
|
Name of Each Exchange
on Which
Each Class is to be Registered
|
Preferred Stock Purchase Rights |
|
New York Stock Exchange |
Securities to be registered pursuant
to Section 12(g) of the Act:
None
(Title of Each Class)
Item 1. Description
of Securities To Be Registered.
On August 28, 2014,
the Board of Directors (the “Board”) of Medifast, Inc., a Delaware corporation (the “Company”),
declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of common stock,
par value $0.001 per share (the “Common Stock”). The dividend is payable on September 9, 2014 to
the stockholders of record on September 9, 2014. The description and terms of the Rights are set forth in a Rights Agreement,
dated as of August 28, 2014 (the “Rights Agreement”), by and between the Company and American Stock Transfer
& Trust Company, LLC, as Rights Agent.
The Board of
Directors adopted the rights plan in response to the recent rapid accumulations of significant portions of the outstanding
Common Stock. The Rights Agreement is intended to enable all stockholders to realize the long-term value of their investment
in the Company and to guard against any attempt to gain control of the Company
without paying all stockholders a premium for that control. The Board of Directors believes that the Rights Agreement
will help promote the fair and equal treatment of all stockholders of the Company and ensure that the Board of Directors
remains in the best position to discharge its fiduciary duties to the Company and its stockholders. In general terms, the
Rights Agreement works by imposing a significant penalty upon any person or group which acquires 10% (or 20% in the case
of certain institutional investors who report their holdings on Schedule 13G) or more of the outstanding Common Stock
without the approval of the Board.
A summary of the terms
of the Rights Agreement follows. This description is only a summary, and is not complete, and should be read together with the
entire Rights Agreement, which has been filed as an exhibit to this Form 8-K. A copy of the Rights Agreement is available free
of charge from the Company.
The Rights. The
Rights will initially trade with, and will be inseparable from, the Common Stock. The Rights are evidenced only by certificates
that represent shares of Common Stock. New Rights will accompany any new shares of Common Stock the Company issues after
September 9, 2014 until the Distribution Date described below.
Exercise Price. Each
Right will allow its holder to purchase from the Company one one-thousandth of a share of Series D Junior Participating Preferred
Stock (a “Preferred Share”) for $110.00 (the “Exercise Price”), once the Rights become exercisable. This
portion of a Preferred Share will give the stockholder approximately the same dividend, voting, and liquidation rights as would
one share of Common Stock. Prior to exercise, the Right does not give its holder any dividend, voting, or liquidation
rights.
Exercisability. The
Rights will not be exercisable until 10 days after the public announcement that a person or group has become an “Acquiring
Person” by obtaining beneficial ownership of 10% (or 20% in the case of certain institutional investors who report their
holdings on Schedule 13G) or more of the outstanding Common Stock.
Certain synthetic interests
in securities created by derivative positions – whether or not such interests are considered to be ownership of the underlying
Common Stock or are reportable for purposes of Regulation 13D of the Securities Exchange Act – are treated as beneficial
ownership of the number of shares of the Common Stock equivalent to the economic exposure created by the derivative position, to
the extent actual shares of the Common Stock are directly or indirectly held by counterparties to the derivatives contracts. Swaps
dealers unassociated with any control intent or intent to evade the purposes of the Rights Agreement are excepted from such imputed
beneficial ownership.
The date when the Rights
become exercisable is the “Distribution Date.” Until that date, the Common Stock certificates will also evidence
the Rights, and any transfer of shares of Common Stock will constitute a transfer of Rights. After that date, the Rights
will separate from the Common Stock and be evidenced by book-entry credits or by Rights certificates that the Company will mail
to all eligible holders of Common Stock. Any Rights held by an Acquiring Person are void and may not be exercised.
Consequences of a Person or Group Becoming an Acquiring Person.
| · | Flip In. If a person or group becomes an Acquiring Person, all holders of Rights except
the Acquiring Person shall thereafter have the right to receive, upon exercise, that number of shares of Common Stock (or, in certain
circumstances, cash, property or other securities of the Company) which equals the Exercise Price divided by 50% of the current
market price per share of Common Stock at the date of the occurrence of such event. |
| · | Flip Over. If the Company is later acquired in a merger or similar transaction
after the Distribution Date, all holders of Rights except the Acquiring Person shall thereafter have the right to receive, upon
exercise, that number of shares of common stock of the acquiring company which equals the Exercise Price divided by 50% of the
current market price of such common stock at the date of the occurrence of the event. |
| · | Notional Shares. Shares held by affiliates and associates of an Acquiring Person,
and notional shares held by counterparties to a Derivatives Contract with an Acquiring Person, will be deemed to be beneficially
owned by the Acquiring Person. |
Preferred Share Provisions. Each one one-thousandth
of a Preferred Share, if issued:
| · | will entitle its holder to quarterly dividend payments of $0.001 per share, or an amount equal
to the dividend paid on one share of Common Stock, whichever is greater; |
| · | will entitle its holder upon liquidation either to receive $1.00 or an amount equal to the payment
made on one share of Common Stock, whichever is greater; |
| · | will have the same voting power as one share of Common Stock; and |
| · | if shares of the Common Stock are exchanged via merger, consolidation, or a similar transaction,
will entitle holders to a per share payment equal to the payment made on one share of Common Stock. |
The value of one one-thousandth
interest in a Preferred Share should approximate the value of one share of Common Stock.
Expiration. The
Rights will expire on August 28, 2015.
Redemption. The
Board may redeem the Rights for $0.001 per Right at any time before any person or group becomes an Acquiring Person. If the Board
redeems any Rights, it must redeem all of the Rights. Once the Rights are redeemed, the only right of the holders of Rights will
be to receive the redemption price of $0.001 per Right. The redemption price will be adjusted if the Company has a stock split
or stock dividends of its Common Stock.
Exchange. After
a person or group becomes an Acquiring Person, but before an Acquiring Person owns 50% or more of the outstanding Common Stock,
the Board may extinguish the Rights by exchanging one share of Common Stock or an equivalent security for each Right, other than
Rights held by the Acquiring Person.
Anti-Dilution Provisions.
The Board may adjust the purchase price of the Preferred Shares, the number of Preferred Shares issuable and the number of outstanding
Rights to prevent dilution that may occur from a stock dividend, a stock split, a reclassification of the Preferred Shares or Common
Stock. No adjustments to the Exercise Price of less than 1% will be made.
Amendments. The
terms of the Rights Agreement may be amended by the Board without the consent of the holders of the Rights. After a
person or group becomes an Acquiring Person, the Board may not amend the agreement in a way that adversely affects holders of the
Rights.
Miscellaneous.
Until a Right is exercised, the holder thereof, as such, will have no separate rights as a stockholder of the Company, including,
without limitation, the right to vote or to receive dividends in respect of the Rights. Although the distribution of
the Rights will not be taxable to stockholders or to the Company, stockholders may, depending upon the circumstances, recognize
taxable income in the event that the Rights become exercisable for Common Stock (or other consideration) or for common stock of
the acquiring company or in the event of the redemption of the Rights as set forth above.
Anti-Takeover Effects. The
Rights may have certain anti-takeover effects. The Rights may cause substantial dilution to any person or group that attempts to
acquire the Company without the approval of the Board. As a result, the overall effect of the Rights may be to render
more difficult or discourage a merger, tender offer or other business combination involving the Company that is not supported by
the Board.
The Certificate
of Designations of Series D Junior Participating Preferred Stock and the Rights Agreement, dated as of August 28, 2014, by
and between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, specifying the terms of the
Rights are attached hereto as exhibits and incorporated herein by reference. The foregoing description of the
Rights is qualified in its entirety by reference to such exhibits.
Item 2. Exhibits.
3.1 Certificate
of Designations of Series D Junior Participating Preferred Stock of Medifast, Inc. (Incorporated by reference to Exhibit 3.1 to
Medifast, Inc.’s Form 8-K filed on August 29, 2013).
4.1 Rights
Agreement, dated as of August 28, 2014, by and between Medifast, Inc. and American Stock Transfer & Trust Company LLC, which
includes the form of Certificate of Designations of Series D Junior Participating Preferred Stock as Exhibit A, the form of Right
Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (Incorporated by reference to Exhibit 4.1
to Medifast, Inc.’s Form 8-K filed on August 29, 2013).
SIGNATURES
Pursuant to the requirements
of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereto duly authorized.
|
MEDIFAST, INC. |
|
(Registrant) |
|
|
|
|
By: |
/s/ Jason L. Groves, Esq. |
|
|
Name: |
Jason L. Groves |
|
|
Title: |
Executive Vice President and |
|
|
|
General Counsel |
Date: August 29, 2014
Exhibit
Index
Exhibit
No. |
|
Description |
3.1 |
|
Certificate of Designations of Series D
Junior Participating Preferred Stock of Medifast, Inc. (Incorporated by reference to Exhibit 3.1 to Medifast, Inc.’s Form 8-K
filed on August 29, 2013).
|
4.1 |
|
Rights Agreement, dated as of August 28, 2014, by and between Medifast, Inc. and American Stock Transfer & Trust Company LLC, which includes the form of Certificate of Designations of Series D Junior Participating Preferred Stock as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (Incorporated by reference to Exhibit 4.1 to Medifast, Inc.’s Form 8-K filed on August 29, 2013). |
Medifast (NYSE:MED)
過去 株価チャート
から 7 2024 まで 8 2024
Medifast (NYSE:MED)
過去 株価チャート
から 8 2023 まで 8 2024